Atheneos Ventures

Auxesia Orion is a company that specializes in tech-enabled, patient-centric therapeutic management aimed at orphan diseases. It focuses on developing innovative therapies that enhance traditional pharmaceutical healthcare, recognizing that medications alone are insufficient for effective treatment. By commercializing advanced technological solutions, Auxesia Orion seeks to provide comprehensive therapeutic capabilities that improve patient outcomes and access to effective therapies for those with rare conditions.

Helios Orion is a San Francisco Bay Area-based corporate strategy advisory firm specializing in the healthcare industry. With a presence in Santa Clara (North America), Barcelona (Europe), Singapore, and Hong Kong (Asia), they partner with innovative healthcare companies, assisting them in growth strategies, leadership team development, raising profile, product development, and global expansion. Their expertise spans drugs, diagnostics, medical devices, digital therapeutics, therapeutic foods, AI-based technology, cross-border collaborations, and connecting key global cities to Silicon Valley's ecosystem.

Renexxion is a biopharmaceutical company focused on developing innovative therapies for patients suffering from functional gastrointestinal disorders. The company is advancing naronapride, an oral gastro-prokinetic drug that operates within the 5-HT4 agonist class. Naronapride is in the late stages of development and is prepared for Phase 3 clinical trials. The drug targets a variety of conditions, including chronic idiopathic constipation, functional dyspepsia, gastroparesis, gastroesophageal reflux disease, Short Bowel Syndrome, enteral feeding intolerance, and postoperative ileus. Renexxion aims to meet the significant unmet medical needs of patients by providing effective treatment options for these challenging disorders.

Armetheon, Inc. is a privately held clinical stage biopharmaceutical company located in the San Francisco Bay area, specializing in the development of innovative drugs to address significant unmet medical needs. The company focuses on creating novel anticoagulants and antibiotics, particularly aimed at treating cardiovascular diseases. Among its development programs, Armetheon is working on an anti-arrhythmic drug candidate designed to treat ventricular tachycardia in patients with implantable cardioverter defibrillators. This advancement seeks to enhance treatment effectiveness, safety, and overall utility for medical professionals.

Armetheon, Inc. is a privately held clinical stage biopharmaceutical company located in the San Francisco Bay area, specializing in the development of innovative drugs to address significant unmet medical needs. The company focuses on creating novel anticoagulants and antibiotics, particularly aimed at treating cardiovascular diseases. Among its development programs, Armetheon is working on an anti-arrhythmic drug candidate designed to treat ventricular tachycardia in patients with implantable cardioverter defibrillators. This advancement seeks to enhance treatment effectiveness, safety, and overall utility for medical professionals.

Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.